drugset / Trial / NCT00346255
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Monoclonal antibodies, such as BB-10901, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed and/or refractory multiple myeloma.
Timeline
- Start
- 2005-04
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lorvotuzumab Mertansine | Monoclonal antibody | — | Intravenous |